-
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Maternal plasma cell-free DNA in the prediction of pre-eclampsia.
Rolnik DL, O'Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2015;45:106-11. pdf -
Maternal and neonatal outcomes in women undergoing bariatric surgery: a systematic review and meta-analysis.
Galazis N, Docheva N, Simillis C, Nicolaides KH.
Eur J Obstet Gynecol Reprod Biol 2014;181:45-53. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
First-trimester maternal plasma cell-free fetal DNA and preeclampsia.
Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH.
Am J Obstet Gynecol 2009;201:472.1-7. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4.